Pilot psychotherapy program for the deprescription of benzodiazepines for anxiety disorders

IF 0.5 Q4 PSYCHOLOGY, CLINICAL Ansiedad y Estres-Anxiety and Stress Pub Date : 2021-01-01 DOI:10.5093/anyes2022a8
Antonieta Also Fontanet, B. Kostov, J. Benavent Àreu, M. Pinyol Martínez, Josep Miquel Sotoca Momblona, A. Benabarre Hernández, A. Sisó-Almirall
{"title":"Pilot psychotherapy program for the deprescription of benzodiazepines for anxiety disorders","authors":"Antonieta Also Fontanet, B. Kostov, J. Benavent Àreu, M. Pinyol Martínez, Josep Miquel Sotoca Momblona, A. Benabarre Hernández, A. Sisó-Almirall","doi":"10.5093/anyes2022a8","DOIUrl":null,"url":null,"abstract":"Introduction: The objective was to implement a pre-experimental pilot psychotherapy program for benzodiazepine deprescription in patients with anxiety disorders in primary care. Methods: Before-after clinical trial without a control group performed in two urban health centers. Patients aged 18-60 years with a diagnosis of anxiety disorder on benzodiazepine treatment were included. The program consisted of seven sessions of individual psychotherapy, and an individualized deprescription schedule. The Goldberg test and SF-12 questionnaire were administered in the first, third and final sessions. Results: Of the 123 patients included, 107 (87%) finished the study, of whom 93 (86.9%) were women, with a mean age of 44.7 years. Most had generalized anxiety disorder diagnosed in the past year. After completing the program, benzodiazepines were withdrawn in 54 out of 86 participants (62.8%); in 14 (16.3%) the dose was decreased, in 6 (7.0%) the dose was maintained and in 12 (13.9%) the dose was increased. There were significant improvements in the mental dimension of the SF-12 and the Goldberg test score. Conclusions: The intervention was useful in deprescibing benzodiazepines, reducing anxiety and improving the quality of life. Introducing such a program in primary care could allow a better approach to anxiety disorders, avoiding polypharmacy.","PeriodicalId":45616,"journal":{"name":"Ansiedad y Estres-Anxiety and Stress","volume":"53 1","pages":""},"PeriodicalIF":0.5000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ansiedad y Estres-Anxiety and Stress","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5093/anyes2022a8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PSYCHOLOGY, CLINICAL","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: The objective was to implement a pre-experimental pilot psychotherapy program for benzodiazepine deprescription in patients with anxiety disorders in primary care. Methods: Before-after clinical trial without a control group performed in two urban health centers. Patients aged 18-60 years with a diagnosis of anxiety disorder on benzodiazepine treatment were included. The program consisted of seven sessions of individual psychotherapy, and an individualized deprescription schedule. The Goldberg test and SF-12 questionnaire were administered in the first, third and final sessions. Results: Of the 123 patients included, 107 (87%) finished the study, of whom 93 (86.9%) were women, with a mean age of 44.7 years. Most had generalized anxiety disorder diagnosed in the past year. After completing the program, benzodiazepines were withdrawn in 54 out of 86 participants (62.8%); in 14 (16.3%) the dose was decreased, in 6 (7.0%) the dose was maintained and in 12 (13.9%) the dose was increased. There were significant improvements in the mental dimension of the SF-12 and the Goldberg test score. Conclusions: The intervention was useful in deprescibing benzodiazepines, reducing anxiety and improving the quality of life. Introducing such a program in primary care could allow a better approach to anxiety disorders, avoiding polypharmacy.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
苯二氮卓类药物治疗焦虑症的处方解除试点心理治疗方案
前言:目的是在初级保健中对焦虑障碍患者进行苯二氮卓类药物去处方的实验前试点心理治疗项目。方法:在两个城市卫生中心进行无对照组的前后临床试验。患者年龄在18-60岁,诊断为焦虑障碍并接受苯二氮卓类药物治疗。该项目包括七次个人心理治疗,以及一个个性化的去处方计划。戈德堡测验和SF-12问卷分别在第一、第三和最后三个阶段进行。结果:纳入的123例患者中,107例(87%)完成研究,其中93例(86.9%)为女性,平均年龄44.7岁。大多数人在去年被诊断出患有广泛性焦虑症。完成该计划后,86名参与者中有54人(62.8%)停用了苯二氮卓类药物;减少剂量14例(16.3%),维持剂量6例(7.0%),增加剂量12例(13.9%)。在SF-12和Goldberg测试分数的心理维度上有显著的改善。结论:干预可有效抑制苯二氮卓类药物,减少焦虑,提高生活质量。在初级保健中引入这样一个项目,可以更好地治疗焦虑症,避免多种用药。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Ansiedad y Estres-Anxiety and Stress
Ansiedad y Estres-Anxiety and Stress PSYCHOLOGY, CLINICAL-
CiteScore
1.60
自引率
8.30%
发文量
7
期刊最新文献
Factor structure and reliability of the Lasher and Faulkender’s Anxiety about Aging Scale in Mexican adults Ansiedad precompetitiva y habilidades psicológicas relacionadas con el rendimiento deportivo How to evaluate coping strategies for stressful situations? Validation of the CSI in a Spanish university population Propiedades psicométricas del Cuestionario de Ansiedad Social para Adultos (CASO) en población Dominicana Diseño y validación de un cuestionario para la detección de Abusos Sexuales Infantiles en personas adultas con adicción
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1